NEW YORK (GenomeWeb) – GIMDx announced today that it has signed an exclusive distribution agreement for IncellDx's single-cell immune-oncology and oncology diagnostic products in China.
Under the terms of the agreement, GIMDx will supply its China-based parent company Guangzhou Improve Medical Instruments with IncellDx component products, which will be kitted and co-labeled for the Chinese in vitro diagnostic market.